Virtual Library

Start Your Search

Jeremy Chee Seong Tey

Author of

  • +

    P1.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 947)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.15-29 - Impact of Radiation Therapy Quality Assurance on Progression-Free and Overall Survival in Randomized Trials of Lung Cancer (ID 12443)

      16:45 - 18:00  |  Author(s): Jeremy Chee Seong Tey

      • Abstract
      • Slides


      To evaluate if the estimates of treatment effect differ between randomized trials (RCTs) that reported radiation therapy quality assurance (RTQA) and RCTs, which did not report RTQA, for treatment of lung cancer (LC) [C1] using curative intent thoracic radiation therapy (TRT).

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We searched MEDLINE for eligible meta-analyses (MAs) of RCTs of LC. For each trial in the selected MAs, we reviewed if RTQA was performed and extracted the hazard ratios (HR) with 95% confidence interval (CI) for progression-free (PFS) and overall survival (OS). We quantify the differences in the estimated intervention effect on PFS and OS by a ratio of HRs (rHRs): the HR for trials that performed RTQA to that of trials that did not perform or report RTQA. An rHR more than 1 would indicate a larger HR for trials that performed RTQA compared to trials that did not perform or report. We estimated a combined rHR across MAs using a random effects MA model. We performed a meta-regression analysis to adjust for potential confounders including cancer type, comparisons type, sample size and single-vs-multi center trial .

      4c3880bb027f159e801041b1021e88e8 Result

      We included six MAs that comprised of six comparisons and 50 RCTs (22 reported RTQA; 28 did not). Trials that performed RTQA showed similar intervention effect on PFS (rHR 0.96, 95% CI 0.82 to 1.12, P value (P) = 0.57, I squared (I2) = 0%) and OS (rHR 1.00, 95% CI 0.88 to 1.15, P = 0.94, I2 = 0%) compared to trials that did not perform or report RTQA, with low heterogeneity across individual MAs. There was no significant change in the summary rHRs after adjusting for potential confounders.

      8eea62084ca7e541d918e823422bd82e Conclusion

      The conduct of RTQA did not modify the estimates of intervention effects on progression-free and overall survival in randomized trials of lung cancer treated with curative intent thoracic radiation therapy.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.